

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.T./

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>					ATTY. DOCKET NO. PC10664A				SERIAL NO. 09/451,641					
					APPLICANT Danchen Gao, et al.				FILING DATE November 30, 1999			GROUP 1618		
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	US	5	5	6	3	1	6	5	10/8/96	Talley, et al.	514	406		
	US	6	2	3	2	4	2	2	5/15/01	Spitz, et al.	526	351		
FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	EP	0	4	8	8	8	5	6	9/27/95	Europe (English language equivalent US Pat No. 6,232,422 cited above)	C01F	5/30		X
	WO	0	0	4	8	5	8	3	8/24/00	International	A61P	25/06		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
		Vane, "Towards a better Aspirin", <i>Nature</i> , Vol. 367, pp. 215-216 (1994)												
		Battistini, et al., "COX-1 and COX-2: Toward the Development of More Selective NSAIDs", <i>Drug News and Perspectives</i> , Vol. 7, pp. 501-512 (1994)												
		Statutory Declaration of Professor Ian Tucker, dated January 4, 2003												
		Römpf Cemie Lexikon, 9. Auflage, Band 3, Georg Thieme Verlag, Stuttgart, 1990; pp. 2368-2370												
		Teng, et al., "Formulation dependent pharmacokinetics, bioavailability and renal toxicity of a selective cyclooxygenase-1 inhibitor sc-560 in the rat", <i>J. Pharm. Pharmaceut. Sci.</i> (www.ualberta.ca/~csp5), Vol. 6(2); pp. 205-210 (2003)												
		Strickley, "Solubilizing Excipients in Oral and Injectable Formulations", <i>Pharmaceutical Research</i> , Vol. 21(2), pp. 201-230 (2004)												

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC10664A	SERIAL NO. 09/451,641
APPLICANT Danchen Gao, et al.			
FILING DATE November 30, 1999		GROUP	1618
Waterbeemd, et al., "Estimation of Solubility, Permeability, Absorption and Bioavailability", <i>Drug Bioavailability</i> , Vol. 8, pp. 207-209			
Davies, et al., "Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib – A selective Cyclo-Coxxygenase-2 Inhibitor", <i>Clin. Pharmacokinet</i> , Vol. 39(3); pp. 225-242 (2000)			
Barnett International's Strategies for Improving Solubility, Practical Applications for Examining, Measuring, Predicting and Automating Solubility, June 2 – 4, 2004, Airport Marriott, Philadelphia, PA (6 pages)			
2004 PSG Technical Conference, Current Pharmaceutical Products, What Was Once Novel is Now Standard, Le Jardin, 8440 Highway 27, Woodbridge, Ontario October 26 – 27, 2004 (8 pages)			
Memet Bahar, Experimental Protocol – Crystallization Experiments, Product: Celecoxib; Preparation Date: 03.09-3.09.2004 (5 pages)			
Davies, et al., "Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis", <i>Expert Opinion on Pharmacotherapy</i> , Vol. 2(1); pp. 139-152 (2001)			
Declaration of Neal M. Davies dated November 17, 2004			
Declaration of Dr. Tambay Taskin dated February 8, 2006			
Kesten, "Control and Optimisation of Cement Quality with Laser Diffraction Particle Size Analysis and Dry Dispersion, Sympatec GmbH, D-38678 Clausthal-Zellerfeld, Germany (1997)			
Clinical Trial Protocol N49-95-02-006, dated September 6, 1995			
Internal redacted Pfizer document dated July 26, 2007 re: particle size analysis of Arti X 200 mg tablets			
Consultant Agreement re: Clinical Trial N49-95-02-006 dated September 20, 1995			
Barber, et al., "A Logical Stepwise Approach to Laser Diffraction Particle Size Distribution Analysis Methods Development and Validation", <i>Pharmaceutical Development and Technology</i> , Vol. 3(2); pp. 153-161 (1998)			
Pharmaceutical Dosage Forms: Tablets, 2 nd Edition, Vol. 2, (1990)			
Jennings, et al., "Particle size measurement: the equivalent spherical diameter", <i>Proc. R. Soc. Lond. A</i> , Vol. 419, pp. 137-149 (1988)			
United States Provisional Patent Application No. 60/047,535, filed May 22, 1997.			
Affidavit of Professor Shimon Benita, filed in support of the Opposition of Teva Pharmaceutical, Ltd. And Trima Israeli Medical Products Maabarot Ltd. in Israel (date unknown)			
Affidavit of Professor Shimon Benita in response to Affidavits submitted by G.D. Searle & Co. by Professor Jurgensen, Dr. Davis and Mr. Goren, filed in Israeli opposition (date unknown)			
Opposition by the Pharmaceutical Industry Chamber of Bolivia dated October, 2000 (English translation)			
Rejection by Republic of Colombia dated March 16, 2005 (English translation)			
Rejection by Costa Rica dated approx. 2008, later overcome. (English translation)			
Affidavit of Dr. Cynthia Webb filed on behalf of Teva Pharmaceutical Industries Ltd. And Trima Israeli Medical Products Ltd. In Israeli opposition (date unknown)			
Affidavit of Professor Avraham Danon, filed on behalf of Teva Pharmaceutical Industries Ltd. And Trima Israeli Medical Products Ltd. In Israeli opposition (date unknown)			
Affidavit of Professor Avraham Danon, in response to Affidavits submitted by G.D. Searle & Co. by Professor Jurgensen, Dr. Davis and Mr. Goren, filed in Israeli opposition (date unknown)			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.T./

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC10664A	SERIAL NO. 09/451,641
		APPLICANT Danchen Gao, et al.	
		FILING DATE November 30, 1999	GROUP 1618
Opposition filed by Association of Pharmaceutical Laboratories in Ecuador dated August, 2000 (English Translation)			
Decision by European Patent Office in Appeal No. T0696/05-3302 dated February 5, 2009			
Opposition decision by European Patent Office regarding European Patent No. EP1049467 dated March 30, 2005			
Notice of Opposition by Teva Pharmaceutical Industries Ltd. and supporting documents dated July 8, 2003 regarding European Patent No. EP1049467			
Opposition by Zentiva, k.s., in Estonia dated February 17, 2010 regarding Patent No. EE 04834			
Opposition by Fako Ltd. in Eurasia regarding Eurasian Patent No. 3363 (English translation)			
Affidavit of Neal M. Davies, Ph.D. dated March 2006, regarding Guatemalan Patent Application No. PI-990203 and US5,563,165			
Final Decision filed in Guatemala ordering the Registry of Intellectual Property to proceed with respective registry regarding PI-1999-0203			
Rejection filed regarding Application No. PI-990203 in Guatemala dated June 16, 2003			
Administrative Appeal Brief regarding Application No. PI-990203 in response to the Guatemalan Examiner's rejection of June 16, 2003			
Submission in Guatemala dated April, 2004			
Israel opposition summations, July 2006 (English translation)			
Opposition Decision by Israel Patent Office dated February 28, 2008 (English translation)			
Appeal to Set Aside Refusal of Application and Reconsideration to Grant Patent to Philippine AN:1-1999-02951 dated July 28, 2009			
Notice of Appeal by Teva Pharmaceutical Industries Ltd. and Trima Israeli Medical Products Maabarot Ltd., filed in Israel, dated June 5, 2009 (English translation)			
Declaration by Neal M. Davies, Ph.D. dated November 10, 2004, filed in the Isreal Opposition			
Response to Statement filed by the Camara de la Industria Farmaceutica, in Venezuela regarding Venezuelan Patent Application No. 1999-002453			
Annulment Action filed in Peru on January 11, 2010			
Appeal filed by Polpharma in Poland regarding Polish Patent No. PL 200957 B1 (English Translation)			
Appeal filed by Zentiva in Poland regarding the granting of Patent No.PL 200957 (English Translation)			
Decision of Industrial Property Office of the Slovak Republic dated April 26, 2010 regarding Slovak Republic Patent No. SK 283510 (English translation)			
Nullity Action filed by Zentiva in Slovak Republic on July 19, 2008 (English translation)			
Opposition arguments by Teva Pharmaceuticals in Israel (date unknown) (English translation)			
Turkish opposition summary by Fako Ilaclari A.S. (June 18, 2001) (English translation)			
Turkish opposition by Professor. Levent Öner dated June 5, 2001 (English translation)			
Turkish opposition by TÜM EKİP İLA, A.S. (2001) (English translation)			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.T./

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. PC10664A	SERIAL NO. 09/451,641
			APPLICANT Danchen Gao, et al.	
			FILING DATE November 30, 1999	GROUP 1618
Turkish opposition by Nobel Ilac Sanayi Ve Ticaret, A.S. dated June 19, 2001 (English translation)				
Turkish opposition statement by Fako Ilacları dated June 18, 2001 (English translation)				
EXAMINER		DATE CONSIDERED		
/Susan Tran/				/Susan Tran/
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.T./